1,1,4,7-Tetramethyldecahydro-1H-Cyclopropaazulen-4-OL for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
1,1,4,7-Tetramethyldecahydro-1H-Cyclopropaazulen-4-OL may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed 1,1,4,7-Tetramethyldecahydro-1H-Cyclopropaazulen-4-OL in detail.
, Endophytic fungi of Aegle marmelos as a source of novel antibacterials and anti-SARS-CoV agents, The European Physical Journal E, doi:10.1140/epje/s10189-026-00565-z
Abstract Drug resistance in microorganisms is a growing global threat, highlighting the urgent need for novel therapeutic agents. This study evaluates the antibacterial and anti-SARS-CoV potential of fungal endophytes isolated from A. marmelos . Among 16 endophytes screened, the ethyl acetate extract of the #3 AMLBF strain ( Fusarium vanettenii ) exhibited the strongest antibacterial activity against several pathogens. This extract showed minimum inhibitory concentrations (MICs) ranging from 0.49 to 0.8 µg/ml. GC/MS analysis of the active extract identified 45 compounds. Furthermore, molecular docking against the SARS-CoV-2 spike glycoprotein revealed nine potential ligands, with Anthraergosta-5,7,9,22-tetren-3-ol p -chlorobenzoate showing the most potent binding affinity (− 10.2 kcal/mol), a value exceeding that of the standard chloroquine (− 6.5 kcal/mol). These results indicate that the organic extract from this fungal strain is a promising candidate for the discovery of new antimicrobial agents. Graphical abstract